Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 175 (1), R41-9

Mechanisms of Oestrogen Receptor (ER) Gene Regulation in Breast Cancer

Affiliations
Review

Mechanisms of Oestrogen Receptor (ER) Gene Regulation in Breast Cancer

J S Carroll. Eur J Endocrinol.

Abstract

Most breast cancers are driven by a transcription factor called oestrogen receptor (ER). Understanding the mechanisms of ER activity in breast cancer has been a major research interest and recent genomic advances have revealed extraordinary insights into how ER mediates gene transcription and what occurs during endocrine resistance. This review discusses our current understanding on ER activity, with an emphasis on several evolving, but important areas of ER biology.

Figures

Figure 1
Figure 1
Oestrogen receptor (ER) uses pioneer factors to associate with DNA. Two critical proteins involved in tethering ER to the DNA include FOXA1 and GATA3. Both FOXA1 and GATA3 are mutated in primary cancers, whereas ER is mutated in metastases. The impact that these mutations have on ER activity is not known. Recently, the crosstalk between different nuclear receptors has become apparent. Progesterone receptor (PR) and androgen receptor (AR) are commonly expressed in ER+ breast cancer and both are known to impinge on ER transcriptional activity. A major challenge involves identifying how we can exploit existing PR and AR ligands for therapeutic use and how the mutations in ER, FOXA1 and GATA3 influence this hormonal crosstalk.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

References

    1. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacological Reviews 2006. 58 685–704. 10.1124/pr.58.4.2 - DOI - PubMed
    1. Brisken C, Ataca D. Endocrine hormones and local signals during the development of the mouse mammary gland. Wiley Interdisciplinary Reviews: Developmental Biology 2015. 4 181–195. 10.1002/wdev.172 - DOI - PubMed
    1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 2005. 97 1652–1662. 10.1093/jnci/dji372 - DOI - PubMed
    1. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998. 95 927–937. 10.1016/S0092-8674(00)81717-1 - DOI - PubMed
    1. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery 2003. 2 205–213. 10.1038/nrd1031 - DOI - PubMed

Substances

Feedback